Friday’s Midday Movers: Ebix (EBIX), Teva Pharmaceutical Industries (TEVA), Aerie Pharma (AERI)

By Carrie Williams

So far Friday, November 15, NASDAQ is up 0.09% and the S&P is up 0.34%. Here are this morning’s most active stocks: Ebix (EBIXResearch Report), Teva Pharmaceutical Industries (TEVAResearch Report) and Aerie Pharma (AERIResearch Report).

Ebix is up 5.07% in midday trading to $34.59. Shares opened today at $32.92. The company has a 52-week low of $32.15 and a 52-week high of $63.89. On the Street’s front, the average 12-month analyst price target for the stock is $46.00, marking a 39.73% potential upside from current levels. In a report issued on November 13, BMO analyst James Fotheringham maintained a Hold rating on EBIX, with a price target of $46.00, which represents a potential upside of 40% from where the stock is currently trading. Over the last 3 months, the insider sentiment on Ebix has been negative based on 11 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Teva Pharmaceutical Industries is up 4.82% in midday trading to $9.93. Shares opened today at $9.47. The company has a 52-week low of $6.07 and a 52-week high of $24.47. On the Street’s front, the average 12-month analyst price target for the stock is $9.64, marking a 1.80% potential upside from current levels. In a report issued on November 12, J.P. Morgan analyst Chris Schott upgraded TEVA to Hold, with a price target of $8.00, which represents a potential downside of 16% from where the stock is currently trading. Separately, on November 11, Gabelli & Co’s Kevin Kedra reiterated a Buy rating on the stock and has a price target of $20.00. Over the last 3 months, the insider sentiment on Teva Pharmaceutical Industries has been negative based on 50 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Aerie Pharma is up 4.06% in midday trading to $19.10. Shares opened today at $18.35. The company has a 52-week low of $17.51 and a 52-week high of $50.10. On the Street’s front, the average 12-month analyst price target for the stock is $42.43, marking a 131.23% potential upside from current levels. In a report released today, Mizuho analyst Difei Yang maintained a Buy rating on AERI, with a price target of $54.00, which represents a potential upside of 194% from where the stock is currently trading. In the last 30 days, insiders purchased $450K worth of AERI shares. Over the last 3 months, the insider sentiment on Aerie Pharma has been positive based on 44 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Trending Stocks Based on Insider Activity >>